cefodizime

02/01/1997 - "Based on the data obtained with this model, once-daily dosing with 1 g cefodizime (i.v.) should be effective against infections due to the commonest Gram-negative bacteria (E. "
07/01/1984 - "The protective effects of HR 221 on experimental infections in mice caused by Staphylococcus aureus Smith, Escherichia coli C-11, Proteus vulgaris GN-76 and Serratia marcescens No. 2 were directly related to its in vitro activity against these strains. "
06/01/1989 - "In this study, cefodizime (CDZM, THR-221) was administered to 34 children with infections and the efficacy was evaluated in 30 patients. "
06/01/1989 - "Clinical trials of cefodizime (CDZM, THR-221) were carried out in pediatric infection. "
06/01/2006 - "Multiple doses of cefodizime are necessary for the treatment of Neisseria gonorrhoeae pharyngeal infection."

01/01/1992 - "The efficacy of cefodizime (CDZ) in lower respiratory tract infections (LRTI) with parenchymal involvement was assessed by the analysis of data from 919 patients who participated in four controlled, randomized studies and three open studies. "
11/01/1990 - "An open multicentre study of the efficacy and tolerance of cefodizime 1 g bd intravenously or intramuscularly in lower respiratory tract infections."
05/01/1997 - "Cefodizime once daily in the treatment of lower respiratory tract infections."
03/01/1997 - "Cefodizime given in single or divided doses for the treatment of lower respiratory tract infection."
01/01/1992 - "Changes in lymphocyte subpopulations in patients treated with cefodizime for acute lower respiratory tract infections."

01/01/1992 - "The efficacy of cefodizime (CDZ) in upper urinary tract infections (UUTI) and complicated lower urinary tract infections (LUTI) was assessed by analysis of the combined results of five clinical trials. "
03/01/1991 - "A randomized, dose comparison study of cefodizime in the treatment of lower urinary tract infections in women."
01/01/1992 - "Cefodizime given once daily for the treatment of upper urinary tract infections and complicated lower urinary tract infections."
08/01/1989 - "In the urinary tract infection group, T1/2(beta) and AUC in the kidneys (infected site) and liver that mainly participate in elimination of cefodizime considerably increased differently from the control group. "
03/01/1991 - "In a prospective randomized study, the efficacy and safety of 1 and 2 g of cefodizime administered as single intramuscular injections were compared in a total of 50 women having either complicated or uncomplicated lower urinary tract infections (LUTI). "

05/01/1995 - "Single daily dose of cefodizime in patients with community-acquired pneumonia: an open-label, controlled, randomized study. "
05/01/1995 - "We conclude that cefodizime 1 g IM once daily is an effective dosing regimen in the treatment of patients with community-acquired pneumonia."
05/01/1995 - "The objective of this study was to compare the clinical and bacteriologic efficacy and safety of cefodizime 1 g intramuscularly (IM) once daily (group A) versus cefodizime 1 g IM twice daily (group B) and versus ceftriaxone 1 g IM once daily (group C) in patients with community-acquired pneumonia. "
01/01/1992 - "Cefodizime has been shown to possess high in vivo antibacterial activity in a variety of experimental infection models involving different body systems and animal species: systemic infections, pneumonia and urinary tract infections in normal mice, intrauterine infections in normal rats, and meningitis in normal rabbits, as well as systemic infections in immunosuppressed animals. "
12/01/1984 - "In the treatment of experimental Klebsiella pneumonia, cefodizime was superior to cefotaxime and cefuroxime. "

01/01/1998 - "The results of the clinical and laboratory study of the efficacy of the prophylactic and therapeutic use of cefodizime (modivid) in patients with chronic calculous cholecystitis and burns are presented. "